Literature DB >> 15294297

The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability.

Michael R Baldwin1, Marite Bradshaw, Eric A Johnson, Joseph T Barbieri.   

Abstract

Botulinum neurotoxin type A (BoNT/A) is the etiological agent responsible for botulism, a disease characterized by peripheral neuromuscular blockade. BoNT/A is produced by Clostridium botulinum as a single chain protein that is activated by proteolytic cleavage to form a 50 kDa light chain (LC, 448 amino acids) and a disulfide bond-linked 100 kDa heavy chain (HC, 847 amino acids). Whilst HC comprises the receptor binding and translocation domains, LC is a Zn2+-endopeptidase that cleaves at a single glutaminyl-arginine bond corresponding to residues 197 and 198 at the C-terminus of SNAP25. Cleavage of SNAP25 uncouples the neural exocytosis docking/fusion machinery. LC/A (LC 1-448) and several C-terminal deletion proteins of LC/A were engineered and expressed as His-tagged fusion proteins in Escherichia coli. LC 1-448 was purified, but precipitated upon storage. Approximately 40% of LC 1-448 was a covalent dimer due to the formation of inter-chain disulfide bond formation at Cys430. Conversion of Cys430 to Ser abolished dimer formation of LC 1-448, but did not improve solubility. Three C-terminal deletion peptides were engineered; LC 1-425 and LC 1-418 were expressed and could be purified as soluble and stable proteins, whilst LC 1-398 was soluble, but not stable to storage. Kinetic studies showed that LC 1-448 and LC 1-425 efficiently cleaved GST-SNAP25 and the fluorescent substrate SNAPtide, while LC 1-418 catalyzed the cleavage of both the SNAP25 and the fluorescent substrate SNAPtide with a similar Km, but at a 10-fold slower kcat. Thus, regions within the C-terminus of LC/A contribute to solubility, stability, and catalysis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15294297     DOI: 10.1016/j.pep.2004.05.009

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  36 in total

1.  The N-terminal to C-terminal motif in protein folding and function.

Authors:  Mallela M G Krishna; S Walter Englander
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-18       Impact factor: 11.205

2.  Crystal structure of botulinum neurotoxin type G light chain: serotype divergence in substrate recognition.

Authors:  Joseph W Arndt; Wayne Yu; Fay Bi; Raymond C Stevens
Journal:  Biochemistry       Date:  2005-07-19       Impact factor: 3.162

3.  The role of exoproteases in governing intraneuronal metabolism of botulinum toxin.

Authors:  Lance L Simpson; Andrew B Maksymowych; Hirokazu Kouguchi; Garrett Dubois; Roop S Bora; Suresh Joshi
Journal:  Protein J       Date:  2005-04       Impact factor: 2.371

4.  An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists.

Authors:  Lisa M Eubanks; Mark S Hixon; Wei Jin; Sukwon Hong; Colin M Clancy; William H Tepp; Michael R Baldwin; Carl J Malizio; Michael C Goodnough; Joseph T Barbieri; Eric A Johnson; Dale L Boger; Tobin J Dickerson; Kim D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-09       Impact factor: 11.205

5.  A high-throughput-compatible FRET-based platform for identification and characterization of botulinum neurotoxin light chain modulators.

Authors:  Dejan Caglič; Kristin M Bompiani; Michelle C Krutein; Petr Čapek; Tobin J Dickerson
Journal:  J Vis Exp       Date:  2013-12-27       Impact factor: 1.355

6.  Catch and Anchor Approach To Combat Both Toxicity and Longevity of Botulinum Toxin A.

Authors:  Lucy Lin; Margaret E Olson; Takashi Sugane; Lewis D Turner; Margarita A Tararina; Alexander L Nielsen; Elbek K Kurbanov; Sabine Pellett; Eric A Johnson; Seth M Cohen; Karen N Allen; Kim D Janda
Journal:  J Med Chem       Date:  2020-09-18       Impact factor: 7.446

7.  Small molecule metalloprotease inhibitor with in vitro, ex vivo and in vivo efficacy against botulinum neurotoxin serotype A.

Authors:  Alan R Jacobson; Michael Adler; Nicholas R Silvaggi; Karen N Allen; Genessa M Smith; Ross A Fredenburg; Ross L Stein; Jong-Beak Park; Xiaochuan Feng; Charles B Shoemaker; Sharad S Deshpande; Michael C Goodnough; Carl J Malizio; Eric A Johnson; Sabine Pellett; William H Tepp; Saul Tzipori
Journal:  Toxicon       Date:  2017-07-08       Impact factor: 3.033

8.  Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.

Authors:  Michael R Baldwin; William H Tepp; Christina L Pier; Marite Bradshaw; Mengfei Ho; Brenda A Wilson; Robert B Fritz; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

9.  Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form.

Authors:  Nizamettin Gul; Leonard A Smith; S Ashraf Ahmed
Journal:  PLoS One       Date:  2010-09-22       Impact factor: 3.240

10.  The C terminus of the catalytic domain of type A botulinum neurotoxin may facilitate product release from the active site.

Authors:  Rahman M Mizanur; Verna Frasca; Subramanyam Swaminathan; Sina Bavari; Robert Webb; Leonard A Smith; S Ashraf Ahmed
Journal:  J Biol Chem       Date:  2013-06-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.